1 **Title:** 

- 2 Multi-channel intraneural vagus nerve recordings with a novel high-density carbon fiber
- 3 microelectrode array
- 5 Authors:

4

8

16

- 6 Ahmad A. Jiman<sup>1,2,3</sup>, David C. Ratze<sup>2,4</sup>, Elissa J. Welle<sup>1,2</sup>, Paras R. Patel<sup>1,2</sup>, Julianna M. Richie<sup>1,2</sup>,
- 7 Elizabeth C. Bottorff<sup>1,2</sup>, John P. Seymour<sup>1,4,5</sup>, Cynthia A. Chestek<sup>1,2,4</sup>, Tim M. Bruns<sup>1,2</sup>
- 9 1- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA
- 10 2- Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA
- 3- Department of Electrical and Computer Engineering, King Abdulaziz University, Jeddah,
- 12 Saudi Arabia
- 4- Department of Electrical Engineering and Computer Science, University of Michigan, Ann
- 14 Arbor, MI, USA
- 15 5- Department of Neurosurgery, University of Texas Health Science Center, Houston, TX, USA
- 17 <u>Corresponding Author:</u>
- 18 Tim M. Bruns, Ph.D.
- 19 NCRC B10 A-169
- 20 2800 Plymouth Road
- 21 Ann Arbor, MI 48109, USA
- 22 Phone: (734) 647-8727
- 23 Email: bruns@umich.edu

### Abstract

Autonomic nerves convey essential neural signals that regulate vital body functions. Recording clearly distinctive physiological neural signals from autonomic nerves will help develop new treatments for restoring regulatory functions. However, this is very challenging due to the small nature of autonomic nerves. We developed a multi-channel, high-density, intraneural carbon fiber microelectrode array (CFMA) for recording physiological action potentials from small autonomic nerves. In this study, we inserted CFMA with up to 16 recording carbon fibers in the cervical vagus nerve of 22 isoflurane-anesthetized rats. We recorded action potentials with signal-to-noise ratios of 2.0-8.3 on multiple carbon fibers per experiment, determined conduction velocities of some vagal signals in the afferent (0.7-1.0 m/sec) and efferent (0.7-8.8 m/sec) directions, and monitored firing rate changes in breathing and blood glucose modulated conditions. Overall, these experiments demonstrated that CFMAs are a novel interface for in-vivo intraneural action potential recordings from autonomic nerves. This work is a milestone towards the comprehensive understanding of physiological neural signaling and the development of innovative treatment modalities for restoring vital functions controlled by autonomic nerves.

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

The autonomic nervous system has a major role in the regulation of unconscious functions that are essential to the body. The system is divided into the sympathetic nervous system, which controls "fight-or-flight" responses, and the parasympathetic nervous system, which regulates "rest-anddigest" functions<sup>1</sup>. A main parasympathetic nerve is the vagus nerve, which innervates many visceral organs, such as the heart, lungs, stomach, liver, pancreas and intestines<sup>2,3</sup>, and contributes to the regulation of numerous autonomic functions, which include breathing, immune responses, digestion, glucose metabolism and others<sup>4–8</sup>. The vagus nerve at the cervical level is partially composed of myelinated A $\delta$  and B fibers<sup>9,10</sup>, but the great majority of axons (over 80%) are unmyelinated C-fibers<sup>2,11,12</sup>. These fibers predominantly convey afferent (sensory) signals from the innervated organs to the central nervous system<sup>13</sup>. Hence, the vagus nerve is an attractive target for monitoring the physiological state of visceral organs for therapeutic or scientific objectives. A class of therapies that has gained considerable interest in recent years is bioelectronic medicine, which targets autonomic nerves to detect and alter neural activity for restoring autonomic functions 14-16. The variety of bioelectronic medicine applications that target the vagus nerve have led to clinical trials on vagus nerve stimulation (VNS) for patients with epilepsy<sup>17</sup>, stroke<sup>18</sup>, depression<sup>19</sup>, rheumatoid arthritis<sup>20</sup>, obesity<sup>21</sup>, and type-2 diabetes<sup>22</sup>, among others. Despite the therapeutic benefits of VNS and bioelectronic medicine, stimulation patterns are generally selected by experimenting with different parameters without monitoring the physiological signaling in the nerve. A key element that is needed to achieve the full potential of bioelectronic medicine is a better understanding of neural signaling in normal and modulated physiological conditions. Recording neural activity from autonomic nerves is very challenging due to the often submillimeter nature of these nerves<sup>23,24</sup>, the protective layers surrounding the nerve (epineurium), bundle of axons (perineurium) and individual axons (endoneurium)<sup>25,26</sup>, and the low-amplitude

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

waveforms generated from small unmyelinated C-fibers<sup>27</sup> that dominate autonomic nerves<sup>28,29</sup>. Studies have applied electrical stimulation on autonomic nerves to record evoked neural activity using extraneural electrodes, which record from outside the nerve<sup>9,30</sup>, and intraneural electrodes, which penetrate the nerve<sup>31</sup>. Although electrical stimulation-evoked responses can be useful in determining the type of activated fibers, these responses do not represent physiological neural signaling. A few research groups have obtained physiological neural recordings from autonomic nerves using extraneural cuff electrodes<sup>32–36</sup>. However, extraneural electrodes lack spatial selectivity, as these electrodes record the compound activity of hundreds to thousands of axons from outside the nerve. Intraneural electrodes penetrate the nerve to be closer to axons and provide better selectivity and higher signal-to-noise ratio (SNR) recordings than extraneural electrodes<sup>25,26</sup>. Intraneural high-density Utah slanted electrode arrays (HD-USEAs) have 48 electrodes (30-100 μm tapered diameter) in a 5x10 configuration (pitch of 200 μm; corner electrodes used as reference and ground) and have been used to record signals in cat pudendal nerves, which have an approximate diameter of 1 mm<sup>37,38</sup>. This configuration of the silicon-based HD-USEA is large (1x2 mm) and rigid for most autonomic nerves, which are often under 1 mm in diameter. For recording from small-diameter ( $\leq 0.5$  mm) autonomic nerves, carbon nanotube (CNT) electrodes have demonstrated high SNR recordings (> 10 dB) in rat glossopharyngeal and vagus nerves (diameter of 100-300 µm)<sup>23</sup>. This was achieved by inserting two CNT electrodes (10 µm in diameter) in a nerve target at a 2-mm separation to obtain a single differential recording. Another research group inserted 4-channel carbon fiber arrays (electrode diameter ≤ 15 μm, pitch of 150 μm) in tracheosyringeal nerves of zebra finch birds, which are 125 μm in diameter and mostly composed of myelinated fibers (99%)<sup>31</sup>. They obtained spontaneous recordings but primarily demonstrated electrical stimulation-evoked compound neural responses. Autonomic nerves are

typically dominated by hundreds to thousands of unmyelinated fibers <sup>28,29,39,40</sup>. The fibers of the vagus nerve in particular innervate multiple critical organs and contribute to the regulation of many autonomic functions<sup>2–8</sup>. Therefore, a need remains for an intraneural electrode array that can record physiological single-neuron activity at multiple sampling locations within small autonomic nerves. Our research group has developed a novel, multi-channel, blowtorch-sharpened, intraneural carbon fiber microelectrode array (CFMA) for small autonomic nerves. The CFMA has ultra-small recording electrodes (8-9 µm in diameter, 150-250 µm in length) in a higher-density configuration than previously reported arrays (16 carbon fibers in 2 rows, with a 132 µm pitch along the array and 50 µm between rows). Prior versions of the CFMA with longer (500-5000 µm), unsharpened carbon fibers have demonstrated high SNR recordings with minimal tissue damage in the rat cerebral cortex<sup>41-44</sup>. We hypothesized that this novel CFMA would obtain physiological action potential recordings with high SNR in small autonomic nerves. In this study, we inserted CFMAs in rat cervical vagus nerves (diameter of 300-500 µm). We recorded action potentials on multiple carbon fibers per experiment, determined the propagation direction and conduction velocity of some vagal signals, and monitored changes in neural activity in breathing and blood glucose modulated conditions.

### **Results**

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

We fabricated CFMAs with 16 carbon fibers in a 2x8 configuration. Fibers within each row had a pitch of 132  $\mu$ m, and the two rows were separated by 50  $\mu$ m (Figure 1a). The carbon fibers, which had a diameter of 8-9  $\mu$ m, were cut to 150-250  $\mu$ m in length and the tips were sharpened with a blowtorch (Figure 1b). The active recording site for a carbon fiber is coated with poly(3,4-

ethylene-dioxythiophene):sodium p-toluenesulfonate (PEDOT:pTS) and spans 135-160 µm in length from the tip. To facilitate CFMA insertion in a rat vagus nerve, we designed a nerve-holder to secure and elevate the vagus nerve away from fluid and breathing motions of the cervical cavity, and allow accurate positioning of a small camera to visualize the CFMA-nerve interface during insertion (Figure 1c).




Figure 1. Carbon Fiber Microelectrode Array (CFMA) and experimental setup. (a) CFMA with 16 blowtorch-sharpened carbon fibers in a 2x8 configuration. (b) Scanning Electron Microscopy (SEM) images of sharpened carbon fibers. Arrows indicate an exposed (non-insulated) carbon fiber region with a length of ~140 μm from the tip. (c) Design of a nerve-holder to facilitate CFMA insertion in a rat vagus nerve. Dimensions of the design are shown in Supplementary Figure 1. (d) Surgical setup for inserting CFMA in the vagus nerve. (e) Timeline for the experimental protocol. An intraperitoneal (IP) dose of glucose, insulin, 2-deoxy-D-glucose, or saline was injected to modulate blood glucose concentration levels.

We inserted 6 CFMAs in the left cervical vagus nerve of 22 Sprague-Dawley rats. We observed neural activity on 167 out of 326 inserted functional carbon fibers (impedance  $< 1 \text{ M}\Omega$ ). The neural

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

activity on each carbon fiber was sorted into 1 neural cluster (n=160) or 2 neural clusters (n=7). The functional carbon fibers had an average impedance of  $31.3 \pm 42.0 \text{ k}\Omega$  (mean  $\pm$  standard deviation) in saline before an experiment,  $70.8 \pm 81.9 \text{ k}\Omega$  in the nerve immediately after insertion, and  $94.7 \pm 146.7 \text{ k}\Omega$  in the nerve at the end of the experiment. Three of the CFMAs were used in more than one experiment (4-8 experiments per CFMA), which initially had a total of 48 functional carbon fibers (16 carbon fibers per CFMA) with an average impedance of  $52.8 \pm 36.8 \text{ k}\Omega$  after insertion in the first experiment. After insertion in the fourth experiment, 45 carbon fibers on these three CFMAs (14-16 carbon fibers per CFMA) remained functional with an average impedance of  $92.6 \pm 149.5 \text{ k}\Omega$ . On average for a single experiment, we made  $2.3 \pm 2.9$  attempts to insert a CFMA with  $14.8 \pm 1.8$  functional carbon fibers and observed neural activity on  $7.6 \pm 5.8$  carbon fibers. There were no distinctive differences among the recordings of rats with different gender or sizes. Multi-Channel Recordings of Vagal Nerve Activity We observed physiological neural activity in the vagus nerve on at least one recording carbon fiber in 19 of the total 22 experiments. The recorded neural activity was sorted into clusters and the mean peak-to-peak amplitudes of the sorted clusters were between 15.1 and 91.7 µV with SNR of 2.0-8.3. An example of vagal nerve activity on multiple recording carbon fibers from the same experiment is shown in Figure 2a. Propagation of vagal signals were detected along adjacent recording carbon fibers in some experiments. We observed neural signals in 10 experiments propagating in the afferent direction with conduction velocities of 0.7-1.0 m/sec over the span of 2-7 carbon fibers (132-792 µm). Furthermore, we monitored efferent signals conducting at 0.7-8.8 m/sec along 2-5 carbon fibers (132-528 µm) in 5 experiments. Examples of propagating afferent signals are shown in Figure 2b

with cross-correlation to inspect the latency of those signals along CFMA carbon fibers (Figure 2c).





Figure 2. Representative recordings of physiological vagal nerve activity and signal propagation along CFMA carbon fibers (CFs). (a) Recordings of vagal nerve activity on 2 carbon fibers (CF 1 and CF 7) in the same experiment showing distinctive signals. The firing of sorted spikes (marked with x) are unique across CFs. (b) Instances of signal propagation along CF 1 – CF 4. (c) Cross correlation of spikes on CF 1 and CF 4. The prevalent latency occurred at -0.6 msec with a count of 174 spikes (55.8% of spikes on CF 4). At latency of -0.6 msec, the spikes occurred on CF 4 before CF 1, suggesting that the signal is propagating in the afferent direction at a conduction velocity of 0.7 m/sec.

### **Breathing-Related Neural Activity**

We observed vagal signals with periodic bursting firing behavior (n=6 experiments) at repetition rates of  $39.4 \pm 10.8$  cycles/min, which were similar to the animals' breathing rates of  $39.3 \pm 9.9$  breaths/min (Figure 3). In a subset of experiments (n=3), we reduced the breathing rate to  $20.0 \pm 10.0$ 

8.0 breaths/min by increasing the depth of anesthesia, and the firing-burst repetition rates reduced to a similar level at  $19.1 \pm 10.3$  cycles/min, with maintained peak-to-peak amplitudes ( $31.7 \pm 11.6$   $\mu V$  to  $29.3 \pm 10.1$   $\mu V$ ) and inter-spike interval (ISI) peak values ( $9.2 \pm 1.6$  msec to  $10.5 \pm 1.6$  msec), as shown in the example in Figure 3a. The periodic bursting behaviors were usually firing at one ISI peak of  $9.5 \pm 1.3$  msec. However, in two experiments, two distinct ISI peaks were observed at  $9.8 \pm 1.8$  msec and  $24.2 \pm 6.0$  msec (e.g. Figure 3b).



**Figure 3. Breathing-related neural activity. (a)** Recordings of vagus nerve activity at 2% and 5% isoflurane. The bursting firing behavior had a repetition rate of 32.2 cycles/min (1/T<sub>1</sub>) during animal's breathing rate of 32 breaths/min at 2% isoflurane. The firing-behavior repetition rate reduced to 14.2 cycles/min (1/T<sub>2</sub>) as the breathing rate reduced to ~12 breaths/min at 5% isoflurane. The average peak-to-peak amplitude (Vpp) and inter-spike interval (ISI) peaks were similar for the spike waveforms at 2% and 5% isoflurane. (b) Bursting firing behavior at two distinct ISIs indicated at the t<sub>1</sub> and t<sub>2</sub> durations. The animal's breathing rate was ~44 breaths/min and the repetition rate for the bursting firing behavior was 47.3 cycles/min (1/[t<sub>1</sub>+t<sub>2</sub>]).

### Neural Firing Rate Behavior in Blood Glucose Modulation Conditions

In each experiment, we recorded vagal nerve activity for a baseline period of at least 5 minutes before the intraperitoneal (IP) injection of a blood glucose modulation dose (glucose, insulin, 2-deoxy-D-glucose, or saline). Recordings were continued for 60 minutes after the injection. Physiological parameters (blood glucose concentration, breathing rate, and heart rate) were measured every 5 minutes throughout the entire experiment. The recorded neural activity were sorted into 174 clusters. The firing rate of these clusters showed moderate or high correlation coefficients ( $|\rho| \ge 0.3$ ) with one (n=15), two (n=35), or all three (n=96) of the tracked physiological parameters. However, correlation coefficients did not show clear associations between any glucose modulation dosing and any of the physiological parameters across experiments. An experiment with a carbon fiber that recorded the activity of 2 sorted clusters, along with the physiological measurements (blood glucose concentration, breathing rate and heart rate) and correlation coefficients, is shown in Figure 4.




Figure 4. Vagus nerve recordings with sorted clusters in an insulin-injected experiment. (a) Filtered signal of a vagus nerve recording, firing rates of the two sorted clusters, and measurements of blood glucose (BG) concentration, breathing rate (BR) and heart rate (HR). The waveforms of the sorted clusters are shown with the average peak-to-peak amplitude (Vpp), signal-to-noise ratio (SNR), and correlation coefficients (ρ) between cluster firing rate and BG, BR and HR measurements. The red boxes in the voltage plot indicate the time-window for the plots in b. (b) Filtered signal of the vagus nerve recording before and after insulin injection, and the spike waveforms of the two sorted clusters within each 10-sec window.

Although correlation coefficients did not show a clear relationship between any of the glucose modulation doses and physiological parameters, we observed clusters with interesting firing rate behaviors after injection of a modulation dose, as shown in Figure 5. In some glucose injection experiments (n=4), we observed neural clusters (n=11) with an average peak-to-peak amplitude of  $24.7 \pm 6.4 \,\mu\text{V}$  with an initial firing rate of  $6.8 \pm 8.9$  spikes/sec that decreased after administration

of glucose to  $1.8 \pm 2.4$  spikes/sec (e.g. Figure 5a). In some experiments with an insulin injection (n=4), neural clusters (n=4) with amplitudes of  $53.3 \pm 28.0 \,\mu\text{V}$  peak-to-peak increased their firing rates from  $1.2 \pm 1.8$  spikes/sec to  $7.6 \pm 10.4$  spikes/sec at 1-13 minutes after insulin administration (e.g. Figure 5b). Injection of 2-deoxy-D-glucose (2-DG) induced a similar neural response to insulin in some experiments (n=2). Starting at 1-9 minutes after 2-DG administration, clusters (n=6) with an average amplitude of  $29.2 \pm 8.1 \,\mu\text{V}$  peak-to-peak increased their firing rates from  $3.8 \pm 4.6$  spikes/sec to  $9.8 \pm 10.1$  spikes/sec (e.g. Figure 5c). A summary of all the performed experiments is shown in Supplementary Table 1.




Figure 5. Examples of sorted clusters and their firing rates in blood glucose modulated conditions. The clusters were observed in blood glucose modulation experiments with an intraperitoneal (IP) injection of (a) glucose, (b) insulin, (c) 2-deoxy-D-glucose (2-DG), or (d) saline. The waveforms of the sorted clusters are shown with the average peak-to-peak amplitude (Vpp), signal-to-noise ratio (SNR), correlation coefficients (ρ) between cluster firing rate and blood glucose (BG) concentration, breathing rate (BR) and heart rate (HR). Blood glucose concentration measurements above 750 mg/dL were not available due to the limitations of the glucometer.

### Discussion

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

We developed a multi-channel, high-density, intraneural carbon fiber microelectrode array (CFMA) for recording neural signals in autonomic nerves (Figure 1). Using the CFMA, we obtained axonal action potential recordings in rat cervical vagus nerves with signal-to-noise ratio (SNR) of 2.0-8.3. We recorded physiological vagal nerve activity that was unique across multiple channels per experiment (Figure 2a), determined the propagation direction and conduction velocity of some vagal signals (Figure 2b), and monitored changes in neural activity in physiologically modulated conditions (Figures 3-5). These data demonstrate CFMA as a new interface for in-vivo intraneural recordings. This work, to our knowledge, is the first to demonstrate in-vivo physiological action potential recordings on multiple channels in a sub-millimeter autonomic nerve. Monitoring physiological signaling in autonomic nerves will help researchers better understand the neural control and feedback processes for autonomic organs, which is a key element for developing innovative treatment modalities to restore vital body functions regulated by autonomic nerves. Our experimental recordings demonstrated CFMA as a multi-channel, intraneural array for smalldiameter (≤ 0.5 mm) autonomic nerves. In prior work, the high-density Utah slanted electrode array (HD-USEA) was implanted in a 1-mm diameter cat pudendal nerve<sup>37</sup>. While the 48-channel, 200 µm pitch HD-USEA (footprint over 1 mm<sup>2</sup>) was used to record physiological signaling from autonomic organs (feline lower urinary tract)<sup>37</sup>, the size of the HD-USEA electrode shanks (300-800 µm in length, 30-100 µm in diameter)<sup>38</sup> are much larger than in the CFMA and would make intraneural recordings in small autonomic nerves challenging. In our study, 16-channel CFMAs (footprint less than 0.05 mm<sup>2</sup>; 132 µm pitch along the array and 50 µm between two rows) with ultra-small electrodes (150-250 µm in length, 8-9 µm in diameter) were implanted in small-

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263


264

265

266

diameter (300-500 µm) rat vagus nerves. Another intraneural electrode that obtained physiological recordings in small-diameter (100-300 µm) autonomic nerves (rat glossopharyngeal and vagus nerves) are carbon nanotube (CNT) electrodes<sup>23</sup>. Two single-channel CNT electrodes were inserted with a 2-mm separation in a nerve target to obtain only a single differential recording in that study. The CFMA recorded physiological neural activity on multiple channels (up to 16 channels), which allowed us to detect the propagation direction and conduction velocity of some signals (Figure 2). The recording exposure site on each carbon fiber spans 135-160 µm in length from the tip, which provided better spatial selectivity recordings than CNT electrodes that had an exposed recording segment of ~500 µm. Another research group developed an intraneural 4channel carbon fiber array with a similar pitch (150 µm) as the CFMA but with longer carbon fibers (≥ 350 µm) that recorded from tracheosyringeal nerves of zebra finch birds (diameter of 125 um)<sup>31</sup>. They demonstrated an innovative blowtorching technique for sharpening carbon fibers to directly insert carbon fibers in a nerve, which we adapted to our shorter (150-250 µm) CFMA carbon fibers. Although an example of spontaneous activity was shown using the 4-channel array, the majority of their demonstrated signals were evoked responses from electrical stimulation. The observed spike waveforms in CFMA recordings from the vagus nerve (e.g. Figures 2-5) are action potentials generated by individual neurons, based on the waveform shape and time scale (1-2 msec)<sup>45,46</sup>. Furthermore, we observed propagation of signals in the afferent and efferent direction within the conduction velocity range for myelinated (Aδ and B) and unmyelinated (C) fibers (Figure 2), which are present in the vagus nerve<sup>9,10</sup>. However, due to the similarity in the waveform shapes and the normal variations in waveform amplitudes, we were not able to sort the detected action potentials into clear single units per channel, with only a few channels yielding more than one sortable cluster. The active recording site for a CFMA carbon fiber spans 135-160 µm in length

from the tip (Figure 1), which exposes the recording site to an estimation of over 200 axons within a distance of 5 µm from the recording site (Figure 6). This estimation is based on the approximate axon density in the rat vagus nerve, which has around 11,000 axons<sup>28,29</sup> contained within a diameter of about 300 µm. Further work on reducing the exposed recording site area may assist in monitoring more localized axon activity with a lower background noise level<sup>24,42,44</sup>. Moreover, current spike-sorting algorithms are mostly designed for central nervous system recordings<sup>47</sup>, which assume the waveforms are from neuron cell bodies that generate higher amplitude waveforms and have more diverse shapes than unmyelinated axons. Future work is needed to study the recording nature in autonomic nerves and develop spike-sorting algorithms for axonal recordings.



**Figure 6.** Immunohistochemistry image of a rat cervical vagus nerve with a diagram of an inserted CFMA carbon fiber. The shaded region on the CFMA carbon fiber is the active recording site. The dashed lines specify an area within a distance of 5 μm from the active recording site of one carbon fiber. The area is estimated to be occupied by over 200 axons based on the typical axon density of a rat vagus nerve (~11,000 axons in 300 μm diameter nerve)<sup>28,29</sup>. The nerve sample in this image was stained with 4', 6-diamino-2-phenylindole (DAPI), myelin basic protein (MBP), and anti-beta III tubuline (TUJ1) to show nucleotides (blue), myelin (green) and axons (red), respectively.

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

Sorted clusters from our recorded vagal nerve activity showed interesting firing rate behavior that may be related to the measured physiological parameters of breathing rate, heart rate and blood glucose concentrations. We observed neural clusters with periodic firing-burst behavior at repetition rates similar to the measured breathing rates (Figure 3). Vagus nerve fibers innervate the lungs, with critical relevance for breathing control<sup>4,48,49</sup>. Our observed vagal signals may be related to the neural control over breathing or an afferent response to chest and/or lung expansion<sup>48</sup>. We also observed interesting changes in vagal firing rate behavior after injection of blood glucose modulation doses (Figure 5). These experiments were performed on fasted rats, and neural signals before the dose injection may represent vagal afferent signals to drive an increase in glucose intake. The firing rate of clusters decreased after administration of glucose (e.g. Figure 5a), which may suggest that the signaling for glucose intake was met. This observation aligns with previous studies that showed neural recordings from dissected fibers of afferent hepatic vagus nerve branches in isolated and perfused livers using wire electrodes<sup>50</sup>, and compound neural activity from the cervical vagus nerve using cuff electrodes after removing the nerve sheath<sup>36</sup>. Both studies demonstrated similar firing rate changes following the administration of glucose. The increase in firing rate observed after insulin or 2-deoxy-D-glucose (2-DG) injection, which induces insulinlike symptoms, may represent a surge of afferent activity to enhance the request for glucose intake (e.g. Figure 5b,c), which aligns with the previously mentioned studies that also showed increased afferent activity in the hepatic branch of vagus nerves using wire electrodes<sup>50</sup>, and increased compound activity of cervical vagus nerves using cuff electrodes<sup>36</sup> within 10 minutes after administration of insulin or 2-DG. However, these observed responses were inconsistent across our experiments with identical injection doses, which may be due to variations in CMFA sampling of neural activity within the nerve. Moreover, there were similarities in the blood glucose

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

concentration trends during an experiment to the other measured physiological parameters (i.e. breathing rate and heart rate) in most experiments (e.g. Figures 4 and 5). The anesthetic agent we used in our experiments was isoflurane, which maintained consistent and stable depth of anesthesia for recording vagal nerve activity with ultra-small carbon fibers. In preliminary experiments using other agents (e.g. ketamine), occasional muscle twitches would lead to CFMA movement or carbon fiber breakage, which were not observed under isoflurane. However, isoflurane anesthesia suppresses neural activity in the central and autonomic nervous systems and impacts multiple physiological parameters, including blood glucose concentration, respiration, and arterial pressure<sup>51,52</sup>. Although this work showed unique in-vivo action potential recordings from the vagus nerve using CFMA, experiments with minimal or no anesthesia would allow more physiological activities to occur and may be necessary to clearly link vagal nerve activity to physiological changes. This work had numerous limitations. The exact insertion location for the CFMA arrays in the vagus nerve varied between our experiments. The rat cervical vagus nerve is estimated to contain around 11,000 axons<sup>28,29</sup> that regulate many autonomic functions<sup>4</sup>. To illustrate this variation, potential breathing-related signals (e.g. Figure 3) were only observed in 6 out of the 22 experiments, although all the rats were breathing normally during the experiments. Furthermore, we detected propagation direction of some, but not all, recorded vagal signals (e.g. Figure 2), likely due to the variation in CFMA insertion alignment along the nerve. Additional work on redesigning the electrode configuration may be needed to cover a wider range of axonal activity while providing high selectivity for individual recording sites, such as with staggered rows of carbon fibers with variable lengths. Another limitation is the requirement to lift the nerve for CFMA insertion, which applies tension on the nerve due to the nerve-holder design. Although the nerve-holder added the

risk of nerve injury, the nerve-holder was necessary to position a camera to visualize the alignment of CFMA carbon fibers with the vagus nerve for insertion (Figure 1). Redesigning the nerve-holder and possibly restructuring the implantation procedure may be needed to eliminate the applied tension and avoid the risk of injuring the nerve. This study only demonstrated CFMA recordings from the rat vagus nerve. However, the CFMA also recorded action potentials from the cat pudendal nerve and rat sural nerve, a branch of the sciatic nerve, in preliminary experiments (data not shown). Future studies on physiological neural recordings from various peripheral nerves will provide new perspectives on neural control processes. Overall, our experiments demonstrated that CFMAs are a novel interface for in-vivo, high-density, multi-channel, intraneural action potential recordings in small autonomic nerves. Further work is needed to refine the selectivity of CFMA and develop a chronic form for long-term, behavioral recordings in autonomic nerves without the presence of anesthesia. This work provided insights in intraneural axonal recordings and is a milestone towards the comprehensive understanding of physiological signaling in autonomic nerves, which may lead to the development of innovative treatment modalities for restoring regulatory functions.

### Methods

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

# Fabrication of Carbon Fiber Microelectrode Array

The independent components for fabricating carbon fiber microelectrode arrays (CFMAs) are described in detail elswhere<sup>42–44,53</sup>. Briefly, a printed circuit board (PCB) was custom manufactured (MicroConnex, Snoqualmie, WA, USA). A connector (A79024-001, Omnetics

Connector Corp., Minneapolis, MN, USA) was soldered on one end of the PCB and covered with epoxy. On the other end, 16 bare carbon fibers (T-650/35 3 K, Cytec Industries, Woodland Park, NJ, USA) with a length of 2-3 mm were attached to the PCB in a 2-row (2x8) configuration. The pitch was 132 µm within a row and the separation between the two rows was 50 µm. The array was coated with approximately 800 nm of parylene-c (PDS 2035, Specialty Coating Systems Inc., Indianapolis, IN, USA) for insulation. The insulated carbon fibers had a diameter of 8-9 µm and were cut down to 150-250 µm in length. The base of the carbon fibers were submerged in water and the tips were sharpened with a blowtorch<sup>31</sup> (MT-51, Master Appliance Corp., Racine, WI, USA) after aligning the carbon fibers with their reflection on the underside of the water surface. The exposed carbon on the sharpened tips (135-160 µm) were electrodeposited with poly(3,4-ethylene-dioxythiophene):sodium p-toluenesulfonate (PEDOT:pTS) by applying 600 pA/fiber for 600 sec. Finally, individual ground and reference wires (AGT05100, World Precision Instruments, Sarasota, FL, USA) were soldered to the PCB.

### Design of Nerve-Holder

To facilitate the insertion of a CFMA in a vagus nerve, we designed a nerve-holder to secure and elevate the vagus nerve away from fluid and breathing motions of the cervical cavity, and allow accurate positioning of a small camera to visualize the CFMA-nerve interface during insertion. The nerve-holder had a hollow center to allow insertion of carbon fibers without breakage, and to drain excess fluid around the nerve which may obscure the camera view. To handle the nerve-holder, a circular threaded rod (21YN67, Grainger Inc., Lake Forest, IL, USA) was inserted in the holder and was connected to a soldering arm (900-015, Eclipse, Amelia Court House, VA, USA). The nerve-holder was designed using a computer-aided design (CAD) software (Fusion 360,

Autodesk, San Rafael, CA, USA) and 3D-printed with clear resin (Form 2, Formlabs, Somerville,

MA, USA). The dimensions of the design are shown in Supplementary Figure 1.

### **Animal Surgery**

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

All experimental procedures were approved by the University of Michigan Institutional Animal Care and Use Committee (IACUC). Non-survival experiments were performed on male (0.48-0.83) kg) and female (0.36-0.42 kg) Sprague-Dawley rats (Charles Rivers Laboratories, Wilmington, MA, USA). The animals were housed in ventilated cages under controlled temperature, humidity, and photoperiod (12-h light/dark cycle), and provided with laboratory chow (5L0D, LabDiet, St. Louis, MO, USA) and tap water ad libitum. The rats were fasted for 3 hours before the procedure. Anesthesia was induced by 5% isoflurane (Fluriso, VetOne, Boise, ID, USA) and maintained at 2-3% isoflurane. Rats were placed on a heating pad (ReptiTherm, Zoo Med Laboratories Inc., San Luis Obispo, CA, USA). A vitals-monitor (SurgiVet, Smiths Medical, Norwell, MA, USA) was used to monitor heart rate with an oxygen saturation (SpO<sub>2</sub>) sensor. A midline ventral cervical incision was made, and retractors (17009-07, Fine Science Tools Inc., Foster City, CA, USA) were used to maintain the cervical opening. Using a dissection microscope (Lynx EVO, Vision Engineering Inc., New Milford, CT, USA), the left cervical vagus nerve (9-12 mm in length) was isolated from the carotid artery and surrounding tissue using fine forceps (00632-11, Fine Science Tools Inc., Foster City, CA, USA). The vagus nerve was lifted (~2 mm) and placed on the nerveholder to facilitate CFMA insertion. The heating pad and dissection microscope were disconnected to reduce electrical noise.

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

**CFMA Insertion** The CFMA was accurately controlled by a micromanipulator (KITE-R, World Precision Instruments, Sarasota, FL, USA) that was secured on an optical breadboard (MB1218, Thorlabs Inc., Newton, NJ, USA) under the animal. The ground wire for the CFMA was inserted subcutaneously in the cervical region and the reference wire was placed in fluid or tissue underneath the nerve-holder. A small pen-shaped camera (MS100, Teslong, Shenzhen, China) was placed in the cervical opening to visualize and align the CFMA fibers for insertion. The nerve was rinsed with saline (0.9% NaCl, Baxter International Inc., Deerfield, IL, USA) and the CFMA was inserted in the vagus nerve. The CFMA was connected to a neural interface processor (Grapevine, Ripple LLC, Salt Lake City, UT, USA) that recorded signals at a sampling rate of 30 kHz on a linked desktop computer. Impedances were measured with the neural interface processor at 1 kHz in saline before the procedure, in the nerve immediately after insertion, and in the nerve at the end of the experiment. Experimental Protocol After completion of surgery and insertion of the CFMA, a baseline recording period of at least 5 minutes was obtained. A dose of glucose (n=6; 1 g, Dextrose 50%, Hospira, Lake Forest, IL, USA), insulin (n=6; 20 U, Vetsulin, Merck Animal Health, Madison, NJ, USA), 2-deoxy-D-glucose (n=6; 60 mg, D8375-1G, Sigma-Aldrich, St. Louis, MO, USA), or saline (n=4; 1.0 mL, 0.9% NaCl, Baxter International Inc., Deerfield, IL, USA) was injected intraperitoneally (IP). Recordings from the CFMA were continued for 60 minutes after the injection. Measurements of blood glucose concentration with a glucometer (AlphaTRAK 2, Abbott, Abbott Park, IL, USA), heart rate with the SpO<sub>2</sub> sensor, and breathing rate with a timer were obtained every 5 minutes. The glucometer was unable to measure blood glucose concentrations above 750 mg/dL in one experiment due to the limitations of the glucometer. In experiments with observed breathing-related neural signals (n=3), a recording period of 1 minute was obtained at 2% isoflurane, followed by a 5-minute recording at 5% isoflurane. At the end of the experiment, animals were euthanized with an overdose of sodium pentobarbital (400 mg/kg IP, Euthanasia Solution, VetOne, Boise, ID, USA).

## Analysis of Neural Recordings

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

The recorded signals were sorted into clusters using Wave\_clus<sup>54</sup>, which is a spike-sorting MATLAB-based algorithm that uses wavelet decomposition to extract waveform features and superparamagnetic clustering to cluster the spikes. The signals were filtered with a band-pass filter at 300-10,000 Hz. The spike detection threshold was set between 3.3 and  $10.1\sigma$  [ $\sigma$  = median( |filtered signal| / 0.6745)|<sup>54</sup>. The sorted clusters were exported to MATLAB (R2014b, MathWorks, Natick, MA, USA) for analysis. Firing rates were calculated with a bin duration of 1 sec. To calculate signal-to-noise ratio (SNR), the mean peak-to-peak amplitude (Vpp) of a sorted cluster was determined and noise intervals with a total duration of at least 7 sec were specified at periods with no occurring spikes or artifacts  $[SNR = Vpp / (2 \text{ x standard deviation of noise})]^{41,43}$ . Crosscorrelation was performed between the sorted clusters across all the recording carbon fibers of a CFMA to inspect the latency of spikes along the CFMA. Latencies with high occurrences (count >> mean occurrence) were identified, and the signal traces on adjacent recording carbon fibers were manually reviewed to confirm instances of signal propagation before determining the conduction velocity and signal propagation direction for these high-occurring latencies. The binsize for the latency counts was set at 0.2 msec, except for one experiment that had multiple high counts at zero latency with this 0.2 msec bin-size resolution. For this experiment only, the bin-size was set at 0.01 msec to provide latency counts with higher resolution. The correlation coefficient

 $(\rho)$  was calculated for all sorted clusters between the firing rate of each cluster and the measured physiological parameters (breathing rate, heart rate and blood glucose concentration) for that experiment. Since the physiological measurements were much less frequent (every 5 minutes) than cluster firing rates (every second), the average cluster firing rate for 1 minute, centered at the time of each physiological measurement, was determined and used for the correlation coefficient computations. When appropriate, data are presented as mean  $\pm$  standard deviation (SD).

### Data Availability

441

442

443

444

445

446

447

451

452

- 448 All raw recordings, sorted neural clusters, and analysis codes will be available on the Blackfynn
- data repository platform at DOI: <a href="https://doi.org/10.26275/j5wc-rwcr">https://doi.org/10.26275/j5wc-rwcr</a> once it has completed NIH
- 450 SPARC data curation.

### References

- 453 1. McCorry, L. K. Physiology of the Autonomic Nervous System. *Am. J. Pharm. Educ.* **71**, 454 (2007).
- 455 2. Agostoni, E., Chinnock, J. E., De Burgh Daly, M. & Murray, J. G. Functional and Histological Studies of the Vagus Nerve and its Branches to the Heart, Lungs and
- 457 Abdominal Viscera in the Cat. J. Physiol. (1957).
- 458 3. Andrews, P. L. R. Vagal afferent innervation of the gastrointestinal tract. *Prog. Brain Res.* 459 **67**, 65–86 (1986).
- 460 4. Berthoud, H. R. & Neuhuber, W. L. Functional and chemical anatomy of the afferent vagal system. *Auton. Neurosci. Basic Clin.* **85**, 1–17 (2000).
- 462 5. Borovikova, L. V *et al.* Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* **405**, 458–462 (2000).
- Browning, K. N., Verheijden, S. & Boeckxstaens, G. E. The Vagus Nerve in Appetite Regulation, Mood, and Intestinal Inflammation. *Gastroenterology* **152**, 730–744 (2017).

- Herthoud, H. R. The vagus nerve, food intake and obesity. *Regul. Pept.* **149**, 15–25 (2008).
- Waise, T. M. Z., Dranse, H. J. & Lam, T. K. T. The metabolic role of vagal afferent innervation. *Nat. Rev. Gastroenterol. Hepatol.* **15**, 625–636 (2018).
- 470 9. Qing, K. Y. *et al.* B fibers are the best predictors of cardiac activity during Vagus nerve stimulation. *Bioelectron. Med.* **4**, 5 (2018).
- 472 10. Kajekar, R., Proud, D., Myers, A. C., Meeker, S. N. & Undem, B. J. Characterization of vagal afferent subtypes stimulated by bradykinin in guinea pig trachea. *J. Pharmacol. Exp. Ther.* **289**, 682–687 (1999).
- Hoffman, H. H. & Schnitzlein, H. N. The numbers of nerve fibers in the vagus nerve of man. *Anat. Rec.* **139**, 429–435 (1961).
- 477 12. Evans, D. H. L. & Murray, J. G. Histological and Functional Studies on the Fibre Composition of the Vagus Nerve of the Rabbit. *J. Anat.* **88**, 320–37 (1954).
- 479 13. Foley, J. O. & DuBois, F. S. Quantitative Studies of the Vagus Nerve in the Cat. I. The Ratio of Sensory to Motor Fibers. *J. Comp. Neurol.* **67**, (1937).
- 481 14. Tracey, K. J. The Revolutionary Future of Bioelectronic Medicine. *Bioelectron. Med.* **1**, 482 (2014).
- 483 15. Birmingham, K. *et al.* Bioelectronic medicines: A research roadmap. *Nat. Rev. Drug Discov.* **13**, 399–400 (2014).
- 485 16. Pavlov, V. A. & Tracey, K. J. Bioelectronic medicine: updates, challenges and paths forward. *Bioelectron. Med.* **5**, 1–4 (2019).
- 487 17. Ben-Menachem, E. Vagus-nerve stimulation for the treatment of epilepsy. *Lancet Neurol.* 488 **1**, 477–482 (2002).
- Dawson, J. *et al.* Safety, feasibility, and efficacy of vagus nerve stimulation paired with upper-limb rehabilitation after ischemic stroke. *Stroke* **47**, 143–150 (2016).
- 491 19. Spindler, P., Bohlmann, K., Straub, H. B., Vajkoczy, P. & Schneider, U. C. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. *Seizure* **69**, 77–79 (2019).
- 494 20. Koopman, F. A. *et al.* Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in Rheumatoid arthritis. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 8284–8289 (2016).
- 497 21. Apovian, C. M. *et al.* Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the 498 Treatment of Obesity in the ReCharge Trial. *Obes. Surg.* **27**, 169–176 (2017).

- 499 22. Shikora, S. a et al. Intermittent Vagal Nerve Block for Improvements in Obesity,
- 500 Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes
- Mellitus: 2-Year Results of the VBLOC DM2 Study. *Obes Surg* (2015)
- 502 doi:10.1007/s11695-015-1914-1.
- 503 23. McCallum, G. A. *et al.* Chronic interfacing with the autonomic nervous system using carbon nanotube (CNT) yarn electrodes. *Sci. Rep.* **7**, 1–14 (2017).
- 505 24. Yan, D. *et al.* Microneedle Penetrating Array with Axon-Sized Dimensions for Cuff-less Peripheral Nerve Interfacing. *Proc. 9th Int. IEEE EMBS Conf. Neural Eng.* 827–830
- 507 (2019).
- 508 25. Micera, S. & Navarro, X. Bidirectional Interfaces with the Peripheral Nervous System. 509 *Int. Rev. Neurobiol.* **86**, 23–38 (2009).
- 510 26. Larson, C. E. & Meng, E. A Review for the Peripheral Nerve Interface Designer. *J.*
- 511 *Neurosci. Methods* **332**, 108523 (2019).
- 512 27. Guo, T. et al. Extracellular single-unit recordings from peripheral nerve axons in vitro by
- a novel multichannel microelectrode array. Sensors Actuators, B Chem. 315, (2020).
- 514 28. Gabella, G. & Pease, H. L. Number of axons in the abdominal vagus of the rat. *Brain Res.*
- **58**, 465–469 (1973).
- 516 29. Prechtl, J. C. & Powley, T. L. The fiber composition of the abdominal vagus of the rat.
- 517 Anat. Embryol. (Berl). **181**, 101–115 (1990).
- 518 30. Ward, M. P. et al. A flexible platform for biofeedback-driven control and personalization
- of Electrical nerve stimulation therapy. *IEEE Trans. Neural Syst. Rehabil. Eng.* **23**, 475–
- 520 484 (2015).
- 521 31. Gillis, W. F. et al. Carbon fiber on polyimide ultra-microelectrodes. J. Neural Eng. 15,
- 522 (2018).
- 523 32. Silverman, H. A. et al. Standardization of methods to record Vagus nerve activity in mice.
- 524 *Bioelectron. Med.* **4**, 1–13 (2018).
- 525 33. Zanos, T. et al. Identification of cytokine-specific sensory neural signals by decoding
- murine vagus nerve activity. *Proc. Natl. Acad. Sci.* in press (2018)
- 527 doi:10.1073/pnas.1719083115.
- 528 34. Shikano, Y., Nishimura, Y., Okonogi, T., Ikegaya, Y. & Sasaki, T. Vagus nerve spiking
- activity associated with locomotion and cortical arousal states in a freely moving rat. *Eur.*
- 530 J. Neurosci. 49, 1298–1312 (2019).
- 531 35. González-González, M. A. et al. Thin Film Multi-Electrode Softening Cuffs for Selective
- 532 Neuromodulation. *Sci. Rep.* **8**, 1–15 (2018).

- 533 36. Masi, E. B. *et al.* Identification of hypoglycemia-specific neural signals by decoding murine vagus nerve activity. *Bioelectron. Med.* **5**, (2019).
- 535 37. Mathews, K. S. *et al.* Acute monitoring of genitourinary function using intrafascicular electrodes: Selective pudendal nerve activity corresponding to bladder filling, bladder fullness, and genital stimulation. *Urology* **84**, 722–729 (2014).
- 538 38. Wark, H. A. C. *et al.* A new high-density (25 electrodes/mm2) penetrating microelectrode array for recording and stimulating sub-millimeter neuroanatomical structures. *J. Neural Eng.* **10**, (2013).
- 541 39. DiBona, G. & Sawin, L. Role of Renal Alpha-2-Adrenergic Receptors in Spontaneously 542 Hypertensive Rats. *Hypertension* **9**, (1987).
- 543 40. DiBona, G. F., Sawin, L. L. & Jones, S. Y. Differentiated sympathetic neural control of the kidney. *Am. J. Physiol.* **271**, R84–R90 (1996).
- 545 41. Kozai, T. *et al.* Ultrasmall Implantable Composite Microelectrodes with Bioactive Surfaces for Chronic Neural Interfaces. *Nat. Mater.* **11**, 1065–73 (2012).
- 547 42. Patel, P. R. *et al.* Insertion of linear 8.4  $\mu$  m diameter 16 channel carbon fiber electrode arrays for single unit recordings. *J. Neural Eng.* **12**, 046009 (2015).
- 549 43. Patel, P. R. *et al.* Chronic in vivo stability assessment of carbon fiber microelectrode arrays. *J. Neural Eng.* **13**, 066002 (2016).
- Welle, E. J. *et al.* Ultra-small carbon fiber electrode recording site optimization and improved in-vivo chronic recording yield. *J. Neural Eng.* (2020).
- 553 45. Moffitt, M. a & McIntyre, C. C. Model-based analysis of cortical recording with silicon microelectrodes. *Clin. Neurophysiol.* **116**, 2240–50 (2005).
- Henze, D. A. *et al.* Intracellular features predicted by extracellular recordings in the hippocampus in vivo. *J. Neurophysiol.* **84**, 390–400 (2000).
- 557 47. Rey, H. G., Pedreira, C. & Quian Quiroga, R. Past, present and future of spike sorting techniques. *Brain Res. Bull.* **119**, 106–117 (2015).
- 559 48. Chang, R. B., Strochlic, D. E., Williams, E. K., Umans, B. D. & Liberles, S. D. Vagal sensory neuron subtypes that differentially control breathing. *Cell* **161**, 622–633 (2015).
- McAllen, R. M., Shafton, A. D., Bratton, B. O., Trevaks, D. & Furness, J. B. Calibration of thresholds for functional engagement of vagal A, B and C fiber groups in vivo .
   *Bioelectron. Med.* 1, 21–27 (2018).
- 564 50. Niijima, A. Glucose-sensitive afferent nerve fibers in the liver and their role in food intake and blood glucose regulation. *J. Auton. Nerv. Syst.* **9**, 207–20 (1983).

566 51. Skovsted, P. & Sapthavichaikul, S. The Effects of Isoflurane on Arterial Pressure, Pulse 567 Rate, Autonomic Nervous Activity, and Barostatic Reflexes. Canad. Anaesth. Soc. J. 24, 568 (1977).569 Carli, F., Ronzoni, G., Webster, J., Khan, K. & Elia, M. The independent metabolic 52. 570 effects of halo thane and isoflurane anaesthesia. Acta Anaesthesiol. Scand. 37, 672–678 571 (1993).53. 572 Welle, E. J. et al. Fabrication and characterization of a carbon fiber peripheral nerve 573 electrode appropriate for chronic recording, in Society for Neuroscience 49th Annual 574 Meeting, Chicago, IL, (2019). 575 54. Chaure, F. J., Rey, H. G. & Quian Quiroga, R. A novel and fully automatic spike-sorting 576 implementation with variable number of features. J. Neurophysiol. 120, 1859–1871 577 (2018).578 579 580 Acknowledgements 581 We thank Dr. Randy Seeley and Dr. Malcolm Low for their advice on designing the experiments, 582 Dr. Zach Sperry, Aileen Ouyang, Eric Kennedy and Dr. Lauren Zimmerman for their assistance 583 in surgical preparation, Joey Letner for his guidance on data analysis, and Dr. Steve Kemp, Dr. 584 Dan Ursu, Jana Moon, Charles Hwang and Sasha Meshinchi for preparing and imaging the 585 immunohistochemistry nerve sample. This research was supported by the National Institute of Health (NIH) Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program (Award 586 587 1OT2OD024907) and the National Science Foundation (Award 1707316). 588 589 590 591

Planned study – AJ, JS, CC, TB. Fabricated arrays – EW, PP, JR, CC. Performed surgeries and collected data – AJ, DR, EB, TB. Analyzed data – AJ, DR, EB, TB. Drafted manuscript – AJ, TB. Reviewed manuscript and approved final version – AJ, DR, EW, PP, JR, EB, JS, CC, TB.

Competing Interests

Authors CAC, EJW, JPS, PRP, AAJ, and TMB are co-authors on a patent application on the development of the carbon fiber microelectrode array. Priority date June 22, 2018. Application # PCT/US2019/038500. The authors declare no other competing interests.

# **Supplementary Information**

603


605


606

# Supplementary Table 1. Summary for all the experiments with inserted CFMA in the vagus nerve.

| ID    | IP Dose | Array | Functional<br>CF | CF with<br>Activity | Clusters | Vpp<br>(μV)    | SNR                 | Clusters with  ρ  ≥ 0.3 |     |     | Signal Propagation (m/sec) |           |                     |
|-------|---------|-------|------------------|---------------------|----------|----------------|---------------------|-------------------------|-----|-----|----------------------------|-----------|---------------------|
|       |         |       |                  |                     |          |                |                     | BG                      | BR  | HR  | Afferent                   | Efferent  | Max<br>Span<br>(μm) |
| 1     | Glucose | Α     | 16               | 16                  | 16       | 21.8 -<br>27.5 | 2.4 -<br>3.1        | 0                       | 0   | 0   | ı                          | ı         | ı                   |
| 2     | 2-DG    | А     | 16               | 6                   | 6        | 18.7 -<br>34.5 | 2.3 -<br>3.5        | 6                       | 6   | 3   | ı                          | ı         | ı                   |
| 3     | Glucose | А     | 15               | 5                   | 5        | 17.9 -<br>29.2 | 2.0 -<br>3.0        | 3                       | 2   | 1   | -                          | -         | -                   |
| 4     | Insulin | Α     | 15               | 14                  | 15       | 23.2 -<br>91.7 | 2.5 -<br>8.3        | 14                      | 15  | 15  | 0.7                        | 0.7       | 396                 |
| 5     | Saline  | Α     | 15               | 7                   | 8        | 22.0 -<br>43.9 | 2.5 -<br>3.5        | 7                       | 7   | 6   | 0.7                        | 0.7       | 264                 |
| 6     | Insulin | Α     | 14               | 0                   | 0        | -              | -                   | -                       | -   | -   | -                          | -         | ı                   |
| 7     | Glucose | В     | 16               | 0                   | 0        | -              | -                   | -                       | -   | -   | -                          | -         | -                   |
| 8     | Insulin | С     | 16               | 7                   | 8        | 20.4 -<br>40.5 | 2.9 -<br>5.3        | 8                       | 8   | 8   | -                          | -         | -                   |
| 9     | Saline  | С     | 16               | 6                   | 7        | 20.7 -<br>59.1 | 3.3 -<br>7.2        | 2                       | 2   | 5   | -                          | 0.7       | 132                 |
| 10    | 2-DG    | С     | 16               | 16                  | 16       | 21.1 -<br>58.7 | 3.0 -<br>6.9        | 13                      | 11  | 14  | 0.7                        | 0.7 - 8.8 | 528                 |
| 11    | Glucose | D     | 16               | 6                   | 6        | 15.1 -<br>38.4 | 2.8 -<br>4.6        | 6                       | 6   | 5   | 0.7                        | -         | 132                 |
| 12    | Insulin | E     | 14               | 5                   | 6        | 17.7 -<br>78.2 | 2.8 -<br>7.9        | 2                       | 6   | 5   | -                          | -         | -                   |
| 13    | 2-DG    | С     | 14               | 2                   | 2        | 27.5 -<br>44.0 | 3.6 -<br>5.7        | 2                       | 2   | 2   | -                          | -         | ı                   |
| 14    | Saline  | Α     | 14               | 14                  | 14       | 27.4 -<br>62.8 | 2.7 -<br>5.5        | 13                      | 14  | 14  | 0.7-0.9                    | ı         | 792                 |
| 15    | Insulin | D     | 16               | 14                  | 16       | 18.7 -<br>54.3 | 2.4 -<br>6.5        | 11                      | 11  | 12  | 0.7                        | ı         | 660                 |
| 16    | 2-DG    | D     | 16               | 13                  | 13       | 17.3 -<br>35.6 | 2.4 -<br>4.0        | 11                      | 9   | 4   | 0.7                        | -         | 792                 |
| 17    | Insulin | D     | 16               | 14                  | 14       | 20.0 -<br>26.6 | 2.8 -<br>3.5        | 11                      | 12  | 11  | 0.7-1.0                    | -         | 528                 |
| 18    | Glucose | D     | 15               | 2                   | 2        | 18.8 -<br>26.0 | 3.1 -<br>3.2        | 2                       | 0   | 2   | 0.7                        | -         | 132                 |
| 19    | 2-DG    | D     | 15               | 4                   | 4        | 19.3 -<br>36.5 | 3.1 -<br>4.7        | 4                       | 4   | 4   | -                          | -         | -                   |
| 20    | Saline  | F     | 8                | 0                   | 0        | -              | -                   | -                       | -   | -   | -                          | -         | -                   |
| 21    | Glucose | Α     | 12               | 1                   | 1        | 26.7           | 2.8                 | 1                       | 1   | 1   | -                          | -         | -                   |
| 22    | 2-DG    | D     | 15               | 15                  | 15       | 27.5 -<br>54.0 | 3.1 –<br>6.4        | 8                       | 10  | 11  | 0.7 - 0.9                  | 0.7       | 528                 |
| Total |         |       | 326              | 167                 | 174      | 15.1 -<br>91.7 | 2.0 <b>–</b><br>8.3 | 124                     | 126 | 123 | 0.7-1.0                    | 0.7 - 8.8 | 132 -<br>792        |

Correlation coefficients ( $\rho$ ) were calculated between cluster firing rates and blood glucose (BG) concentrations, breathing rate (BR) and heart rate (HR) measurements.





**Supplementary Figure 1. Nerve-holder design for inserting CFMA in a rat cervical vagus nerve.** Dimensions are in millimeters (mm).